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Complex barriers at the brain’s surface, particularly in development, are poorly defined.
In the adult, arachnoid blood-cerebrospinal fluid (CSF) barrier separates the fenestrated
dural vessels from the CSF by means of a cell layer joined by tight junctions. Outer
CSF-brain barrier provides diffusion restriction between brain and subarachnoid CSF
through an initial radial glial end feet layer covered with a pial surface layer. To further
characterize these interfaces we examined embryonic rat brains from E10 to P0 and
forebrains from human embryos and fetuses (6–21st weeks post-conception) and adults
using immunohistochemistry and confocal microscopy. Antibodies against claudin-11,
BLBP, collagen 1, SSEA-4, MAP2, YKL-40, and its receptor IL-13Rα2 and EAAT1 were
used to describe morphological characteristics and functional aspects of the outer brain
barriers. Claudin-11 was a reliable marker of the arachnoid blood-CSF barrier. Collagen
1 delineated the subarachnoid space and stained pial surface layer. BLBP defined
radial glial end feet layer and SSEA-4 and YKL-40 were present in both leptomeningeal
cells and end feet layer, which transformed into glial limitans. IL-13Rα2 and EAAT1
were present in the end feet layer illustrating transporter/receptor presence in the outer
CSF-brain barrier. MAP2 immunostaining in adult brain outlined the lower border of glia
limitans; remnants of end feet were YKL-40 positive in some areas.We propose that outer
brain barriers are composed of at least 3 interfaces: blood-CSF barrier across arachnoid
barrier cell layer, blood-CSF barrier across pial microvessels, and outer CSF-brain barrier
comprising glial end feet layer/pial surface layer.
Keywords: arachnoid blood-CSF barrier, development, outer CSF-brain barrier, pial microvessel blood-CSF barrier,
SSEA-4, subarachnoid space, YKL-40
Introduction
For decades the meninges have been considered to be no more than a protective shield, but increas-
ing evidence suggests that the complex outer barriers of the brain also function as morphogenic
signaling centers (Siegenthaler and Pleasure, 2011; Decimo et al., 2012), dynamic transport systems
(Yasuda et al., 2013), a stem cell niche (Decimo et al., 2012) and regulators of immune cell entry to
the CNS (Stolp et al., 2013). Outer brain barriers have so far been treated as a single entity although
it is well-established that they are composed of several independent cellular components. In this
study we aimed to combine a short review of what is known in the field with new data describing
Abbreviations: BBB, blood-brain barrier; BLBP, brain specific lipid-binding protein; CSF, cerebrospinal fluid; EFL, end feet
layer; EM, electron microscopy; GFAP, glial fibrillary acidic protein; PSL, pial surface layer; SAS, subarachnoid space; SSEA-4,
stage-specific embryonic antigen-4.
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arachnoid, pial, and brain surface development in rat and
human.
The Meninges
In addition to the blood-brain and the classical blood-CSF (across
the choroid plexus) barriers, the arachnoid barrier is a third bar-
rier forming an important interface between blood and CSF in
the brain. Dyes injected into the blood tend to stain dura but not
the arachnoid suggesting that the arachnoid rather than the dura
prevents entry of blood-borne substances into the subarachnoid
space (Broman, 1949). Later, ultrastructural electron microscop-
ical (EM) and freeze fracture studies described the arachnoid as a
multi-layered epithelium with tight junctions between cells of the
outer continuous 1–3 cellular layers—the arachnoid barrier cell
layer—that forms an effective seal covering the inner dural sur-
face (Nabeshima et al., 1975; Rascher and Wolburg, 1997). The
pia and the inner layer of arachnoid comprise one cell type—
the leptomeningeal cell—covering the outer-most layer of ner-
vous tissue of the brain, the glia limitans, which is composed
of a dense multilayered meshwork of astrocytic processes cov-
ered by an outer basement membrane. The layers of develop-
ing human meninges were investigated and defined by O’Rahilly
and Muller (1986) starting with the primary meninx comprising
neural crest-derived cells (Decimo et al., 2012) that initially sur-
round the neural tube and at around 6th week post-conception
(wpc) are present around most parts of the brain. Later 6 lay-
ers develop consisting of subcutaneous tissue, the skeletogenous
layer (the dense mesenchyme between the subcutaneous layer
and at first the primary meninx), dura mater, the dural limiting
layer (probably contributing to both dura and arachnoid), lep-
tomeninx (arachnoid and pia), and cerebral wall (O’Rahilly and
Muller, 1986).
Differentiation of the meninges also involves formation of the
subarachnoid space. Thus, the spaces that appear in the inner
reticulated layer of the primary meninx become confluent and
develop into the subarachnoid space and cisterns during late
embryonic and early fetal period. Leptomeningeal cells condense
at the inner surface of the dura and become arachnoid barrier
cells and at the brain surface they form the pial surface layer.
In newborn rat and in early fetal human brain the subarach-
noid space extends from the arachnoid barrier cell layer to the
basement membrane of the pial surface layer and contains CSF
and blood vessels bridged by leptomeningeal cells that also form
traversing arachnoid trabeculae (see Discussion).
Recent investigations have changed the established view of
the meninges as merely protective membranes suggesting that
they contribute to neural tissue homeostasis by secreting several
trophic factors including FGF2, insulin-like growth factor-II and
CXCL12/SDF-1 (Decimo et al., 2012) and they are highly respon-
sive to principal mitogens and necessary for survival and growth
of the developing brain (Decimo et al., 2012). In the fetal brain the
meninges act as a morphogenetic center via secretion of retinoic
acid which regulates neural migration and positioning, and orga-
nize the pial basement membrane, a critical anchor point for the
radially oriented fibers of neuroepithelial stem cells and radial
glial cells, through a variety of other secreted diffusible factors
(Siegenthaler and Pleasure, 2011; Decimo et al., 2012).
The End Feet Layer
The neuroepithelial cell layer of the prosencephalon and early
telencephalon covered with basement membrane faces the out-
side world prior to a forth-coming subarachnoid space. Along
with the differentiation of neuroepithelial cells to radial glia the
radial glial end feet layer covered with a basement membrane
and flattened leptomeningeal cells forms a continuous interface
between the telencephalic wall and the early subarachnoid space.
Glial transformation from radial glial cells to astrocytes begins
in the second trimester in humans and between 25 and 28 wpc
the subpial radial glial end feet layer seems to start transform-
ing into a subpial glia limitans (Kadhim et al., 1988) consisting of
interdigitating astrocytic processes and a few fibrous astrocytes.
Kadhim et al. (1988) found that late subpial end feet were almost
free of autophagic and lysosomal hyperactivity indicating that the
end feet layer and subsequent glia limitans are created from radial
glial cells that do not undergo lysosomal autolysis.
The morphology of the barrier interface over the surface of
the brain is most complex during its early development. Thus, in
addition to the adult barrier of tight junctions linking subdural
arachnoid cells and endothelial cells of blood vessels in the sub-
arachnoid space (Nabeshima et al., 1975), there is a whole array
of specialized intercellular junctions over the pial surface of the
brain. This has been described in the rat embryo where a progres-
sive appearance of distinct junctional structures between the glial
end feet was observed from E14; analysis of albumin distribution
at the EM level suggested that the junctions may contribute to
restriction of diffusion between the subarachnoid space and the
brain extracellular fluid (Balslev et al., 1997). Nabeshima et al.
(1975) noted gap junctions between end feet in the glia limitans
in different mammals, which has been confirmed by others (e.g.,
Balslev et al., 1997; Feig and Haberly, 2011). The glia limitans
has also been found to harbor specialized transmembrane protein
complexes, andmay contribute to neural regulation of blood flow
through pial arteries, homeostatic regulation of K+ andwater and
modulation of neural activity (Feig and Haberly, 2011). It must
therefore be perceived as an important interface in the brain bar-
rier system, albeit studies regarding the barrier properties of this
outer CSF-brain barrier are scarce.
Brain Barriers and Terminology
Many names have been applied to the outer brain barriers, which
complicate interpretation of results. The outer CSF-arachnoid
barrier layer is identical with the blood-arachnoid barrier and the
arachnoid barrier cell layer. The subarachnoid space with its con-
tents extends from the arachnoid barrier cell layer to the outer
CSF-brain barrier. The outer CSF-brain barrier changes during
development from a radial glial end feet layer covered by the
inner-most part of the pial surface layer which initially consists
of a pial basement membrane and a condensed layer of single
leptomeningeal cells to a glia limitans formed by astrocytic end
feet and surface associated astrocytes covered by a pial basement
membrane and scattered associated leptomeningeal cells. This
outer CSF-brain barrier and its individual components have also
been referred to as glial limiting membrane, external pial limiting
membrane, glial end feet barrier, pia-arachnoid end feet barrier
and other names, which sometimes interchange and therefore
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further obscure results. The arachnoid barrier cell layer and outer
CSF-brain interface have also been classified as one barrier and
labeled the pia-arachnoid-brain barrier and in some cases the
outer CSF-brain barrier is completely ignored.
The prevailing classification of brain barriers in the developing
brain has until now included an arachnoid barrier, a blood-brain
barrier, a blood-CSF barrier (across the choroid plexus) and a
CSF-brain barrier (across the ventricular zone) (Saunders et al.,
2008, 2013). In this study we define brain interfaces that pro-
vide diffusion restriction as barriers, and taking into account the
confusion in terminology, we define the terms used: The blood-
CSF barrier, often only defined as the barrier across the choroid
plexus, also encompass the barrier across the arachnoid barrier
cell layer and the pial microvessels, since these interfaces provide
a barrier between blood and the CSF. We name them the arach-
noid blood-CSF barrier across the arachnoid barrier cell layer
and the pial microvessel blood-CSF barrier across pial microves-
sels, with the proviso that the subarachnoid space in the very
early embryonic brain does not exist yet nor does it contain CSF,
since the choroid plexuses have not started their production yet.
The barrier in the pial microvessels has been used as a surrogate
for the blood-brain barrier (Allt and Lawrenson, 1997). This is
incorrect since the neurovascular unit, which contributes to the
fully differentiated blood-brain barrier (Engelhardt and Coisne,
2011) is not present in the subarachnoid space, and given the fact
that pial microvessels are not part of the blood-brain interface,
only the barrier across brain parenchymal blood vessels should be
referred to as a blood-brain barrier proper (BBB). The CSF-brain
barrier consists of both an outer CSF-brain barrier (described
here) across the radial glial end feet layer covered by a pial surface
layer and later in development glia limitans with accompanying
pial basement membrane, and an inner CSF-brain barrier (gener-
ally referred to as CSF-brain barrier) across the ventricular zone
cell layer.
Outer Brain Barriers in Rat and Human
Development
The interfaces at the surface of the developing brain comprise
the arachnoid blood-CSF barrier and outer CSF-brain barrier
separated by a subarachnoid space containing pial microvessels,
which form the pial microvessel blood-CSF barrier. As stated
above, little is known about the changes in outer barriers of the
brain during development. In addition the outer CSF-brain bar-
rier has been largely ignored partly because of known lack of
obvious tight junctions (Balslev et al., 1997). It is now evident that
brain barriers are more than just the presence of tight junctions,
and it is therefore necessary to characterize, divide and define
these complex barriers at the surface of the developing brain.
To this end, we examined embryonic rat brains from E10 to P0
and the outer brain barrier site in human forebrain samples from
human embryos and fetuses (6–21st weeks post-conception) and
adult brain samples using immunohistochemistry and confocal
microscopy. An array of various specific antibodies was used
against tight junctions (claudins), radial glial cells, glial cells, and
neurons (BLBP, EAAT1, GFAP, MAP2).
In a recent study we found YKL-40 mRNA expression
in meninges, telencephalon and choroid plexus and YKL-40
immunostaining of sites at all interfaces of the barriers in the
developing human brain (Bjørnbak et al., 2014). Our results
suggested that YKL-40 secretion from choroid plexus epithe-
lium, leptomeningeal cells, and pericytes may play a main
role associated with transport across the entire mesenchy-
mal/neuroectodermal interface (Bjørnbak et al., 2014). Further-
more, the overall distribution of YKL-40 in the developing
human forebrain was noted to be very similar to that of SSEA-
4 in forebrains of embryos and early fetuses (Barraud et al., 2007)
from this same collection. Therefore, we included antibodies
against SSEA-4, YKL-40 and IL-13Rα2, an YKL-40 receptor.
Materials and Methods
Tissue Samples
Forebrains from two human embryos [7 and 31mm crown-rump
length (CRL)] and 11 fetuses (38–200mm CRL) correspond-
ing to 6–21st weeks post-conception (wpc) and two adult brain
specimens were examined. The embryos and the fetuses were
obtained from legal abortions, as previously described (Bjørnbak
et al., 2014). The adult brain samples were donated for research
following neurosurgery. Informed consent was obtained from
all contributing women following oral and written information,
in accordance with the Helsinki declaration II, and approved
by the Research Ethics Committee of the Capital Region (KF–
V.100.1735/90). Post-operational treatment consisted of imme-
diate dissection of the samples into blocks, that were fixed for 12–
24 h at 4◦C in either 10% neutral buffered formalin, 4% Formol-
Calcium, Lillie’s or Bouin’s fixatives. Rat embryos, 4 for each age
at E12, 14, 16, 18, and P0 (the day of birth) fixed by immer-
sion in either 10% neutral buffered formalin or Bouin’s fixa-
tives were available from a previous investigation (Balslev et al.,
1997). Prior to paraffin embedding, the specimens were dehy-
drated with graded alcohols, and cleared in xylene. For single and
double immunohistochemical experiments, 3–10µm thick serial
sections were cut in transverse, sagittal or horizontal planes, and
placed on silanized glass slides.
Immunohistochemistry
Sections were deparaffinized in xylene and rehydrated using
graded alcohols following standard protocols. Endogenous per-
oxidase was quenched using a 0.5% solution of hydrogen perox-
ide in methanol for 15min. Following rinses with TRIS buffered
saline (TBS, 5mMTris-HCl, 146mMNaCl, pH 7.6), non-specific
binding was inhibited by incubation for 30min with block-
ing buffer (Dako REAL™, S2022, Dako, Glostrup, Denmark) or
0.2% casein (C-7078, Sigma-Aldrich, St. Louis, MO, USA) at
room temperature. Prior to overnight incubation at 4◦C with
primary antibodies diluted in blocking buffer, some antibod-
ies required heat induced epitope retrieval with either citrate
buffer (pH6) or TEG buffer (pH9) (Table 1). Before develop-
ing the signal, sections were washed with TBS. For bright field
light microscopy analysis, the REAL™ EnVision™Detection Sys-
tem, Peroxidase/DAB+ rabbit/mouse, (K5007, Dako, Glostrup,
Denmark) was used for detecting mouse and rabbit primary
antibodies. The sections were washed with TBS, followed by
incubation for 10min with 3,3′-diamino-benzidine chromogen
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TABLE 1 | List of primary antibodies.
Primary antibodies Host IgG Dilution HIER Producer Code number
BLBP Rabbit IgG 1:2000 - Millipore ABN14
Claudin-11/OSP Rabbit IgG 1:1500 - Abcam ab53041
Collagen 1 Rabbit IgG 1:500 citrate, pH6 Abcam ab292
EAAT1 Rabbit IgG 1:400 TEG, pH9 Abcam ab416
GFAP Rabbit IgG 1:10000 TEG, pH9 Dako Z0334
IL-13Rα2 Rabbit IgG 1:100 - Proteintech 11059-1-AP
MAP2 Clon HM-2 1:10000 TEG, pH9 Sigma Aldrich M4403
SSEA-4 Mouse IgG3 1:50/1:100 - Millipore MAB4304
YKL-40 Rabbit IgG 1:10 - Proteintech 12036-1-AP
YKL-40 Mouse, IgG2kb 1:50/1:100 - ∗ 201.F9
HIER, Heat Induced Epitope Retrival. TEG, TRIS + ethylene glycol tetraacetic acid buffer. Producers, Abcam, Cambridge, United Kingdom; Millipore, Merck Life Science, Hellerup,
Denmark. Dako, Glostrup, Denmark. Sigma-Aldrich, St. Louis, MO, USA. Proteintech, Manchester, United Kingdom. ∗Kind gift from Prof. Paul A. Price, UCSD, USA.
solution. Positive staining was recognized as a brown color. The
sections were counterstained withMayers hematoxylin and dehy-
drated in graded alcohols followed by xylene and coverslipped
with DPX mounting media. For double labeling immunoflu-
orescence, sections were incubated for 30min at room tem-
perature with labeled polymer–HRP anti-mouse (EnVision™+
System/HRP, K4007, Dako, Glostrup, Denmark). In order to
amplify the immunoreaction, this was followed by incubation
with a tyramide signal amplification kit with Alexa Fluor 488-
labeled tyramide (1:200, T20912, Life Technologies, Carlsbad,
CA, USA) for 7min at room temperature. Subsequently, the
sections were incubated for 30min at room temperature with
biotin-SP-conjugated F(ab′)2 fragment donkey anti-rabbit anti-
bodies (1:200, 711-066-152, Jackson ImmunoResearch Europe,
Suffolk, United Kingdom) followed by streptavidin-conjugated
DyLight 594 (1:200, SA5594, Vector Laboratories Europe, Peter-
borough, United Kingdom). Finally, a nuclear counterstain with
DAPI (1:1000, D1306, Life Technologies, Carlsbad, CA, USA)
was added for 3min, before sections were coverslipped. Dou-
ble labeling was performed with the combination of antibod-
ies against BLBP and SSEA-4, YKL-40 and SSEA-4, YKL-40
and IL13-Rα2, and YKL-40 and EAAT1. Details of the pri-
mary antibodies including dilutions and suppliers are listed in
Table 1. Staining specificity of the monoclonal YKL-40 anti-
body was thoroughly tested on the same material in a recent
study (see Figure 1 in Bjørnbak et al., 2014), and in addition
the polyclonal anti-YKL-40 used here resulted in an immunos-
taining identical to that of monoclonal YKL-40. Control sec-
tions were incubated with mouse IgG1, IgG2a or irrelevant rabbit
antibodies, as well as subjected to omission of primary or sec-
ondary antibodies. These were always blank. The staining pat-
terns were similar irrespective of different methods of fixation
used as also emphasized in many studies based on the same
collection (e.g., Møllgård and Jacobsen, 1984; Johansen et al.,
2007).
For laser scanning confocal microscopy a Carl Zeiss LSM 780
was used. During image acquisition, a sequential scan procedure
through the z-axis of the double-labeled sections was applied
when applicable, covering in total 9–11µm in depth. Confocal
images were taken and analyzed throughout the z-axis of the
section, and individual optical sections were stored as TIFF files
using Zeiss ZEN Vision v10. Representative images were chosen
for figure editing using Adobe Photoshop CS6.
Results
The meninges and outer brain barriers form during embryo-
genesis and early fetal life. Many factors are involved in this
dynamic process and are necessary for adequate brain develop-
ment. O’Rahilly and Muller (1986) described development of
the human meninges according to Carnegie stages, but have
recently revised this staging model (O’Rahilly and Muller, 2010).
In Table 2 a summary of important events in the development of
the human meninges and outer CSF-brain barrier approximated
to weeks post-conception (wpc) is provided. Results in Carnegie
stages have been translated according to the revision by O’Rahilly
andMuller (2010) and frommammals to human according to the
work of Clancy et al. (2001).
We aimed to characterize the interfaces at the surface of
the developing brain revealing a claudin-11 positive arachnoid
blood-CSF barrier, collagen 1 positive subarachnoid space and
pial surface layer, SSEA-4/YKL-40 positive leptomeningeal cells
and SSEA-4/YKL-40/IL-13Rα2/BLBP positive radial glial end
feet. Each interface is described and discussed in the context of
possible functional significance for the developing brain.
The Arachnoid Blood-CSF Barrier Becomes
Increasingly Claudin-11 Positive During Rat and
Human Brain Development
Previously we have described the developing rat glial end feet bar-
rier prior to the appearance of the arachnoid membrane and thus
before the establishment of a well-defined subarachnoid space
(Balslev et al., 1997). In a recent study of the embryonic mouse
brain immunostained for claudin-11, a distinct reactivity cor-
responding to the developing arachnoid blood-CSF barrier was
found (Whish et al., 2015). Therefore, we decided to test claudin-
11 as a possible marker for the arachnoid blood-CSF barrier
development in rat and human in order to compare this barrier
with the developing outer CSF-brain barrier described previously
in the rat (Balslev et al., 1997).
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TABLE 2 | Features of outer brain barrier and meningeal development.
WPC Feature Species References
6th Appearance of a primary meninx around most parts of the brain Human O’Rahilly and Muller, 1986
Amoeboid microglial cells penetrate the brain by crossing the pial basement membrane Human Verney et al., 2010
7th The skeletogenous layer becomes visible Human O’Rahilly and Muller, 1986
Differentiation of a leptomeningeal meshwork that is presumed to contain liquid and represent
the future SAS
Human O’Rahilly and Muller, 1986
8th The dural limiting layer is almost complete in hindbrain and midbrain but only present in the
area adjacent to the lateral fossa in the forebrain
Human O’Rahilly and Muller, 1986
The fenestrated sinusoids of the pia-arachnoid become non-fenestrated (E14) Rat (E14) Balslev et al., 1997
Most of the cisternae of the adult is already present Human O’Rahilly and Muller, 1986
7–10th Initial communication between the ventricular and subarachnoid compartments Human and rat (E17) Brocklehurst, 1969;
Johansson et al., 2008
11th Completion of the subpial end feet layer (E16) and claudin-11 positive arachnoid blood-CSF
barrier (E18) and thereby appearance of a clearly defined subarachnoid space
Rat (E16 and E18) Balslev et al., 1997
12–13th Second wave of microglial cells penetrate the brain via the BBB and inner CSF-brain barrier Human Verney et al., 2010
12 (13–15th) RGCs begin to transform into astrocytes Rhesus monkey (E64)
and newborn ferret
Schmechel and Rakic,
1979; Voigt, 1989
25–28th Transition from subpial end feet layer to glia limitans Human Kadhim et al., 1988
Data were mainly based on human material and approximated to weeks post-conception. It is clearly stated when results from other mammals are used. The work of Clancy et al. (2001)
was used for conversion to estimated human age.
Early developing rat brain from E10 to E14 showed a complete
lack of claudin-11 immunoreactivity. At E15 a faint immunos-
taining for claudin-11 was present corresponding to loosely
packed arachnoid barrier cells at the base of the brain and to
the developing barrier layer of the future tentorium cerebelli (not
illustrated). At E18 meninges, the subarachnoid space and cis-
terns were fully developed and immunostaining for claudin-11
demonstrated a strong distinct reactivity of the entire arachnoid
blood-CSF barrier (Figures 1A,B). The barrier cell layer was par-
ticularly prominent corresponding to tentorium cerebelli and the
base of the brain and interrupted only where cranial nerves pene-
trated the combined dura-arachnoid (Figure 1A). The arachnoid
barrier cell layer of the forebrain consisted of a single cell layer
shown in Figure 1B. In late embryonic human brain claudin-11
reactivity was first observed as a loose faintly stained meshwork
of leptomeningeal cells surrounding the lower brain stem. At 8th
wpc arachnoid barrier cells at tentorium cerebelli and at the base
of the brain were positive. In the second trimester meninges,
the subarachnoid space and cisterns were fully developed. At
mid-gestation the arachnoid blood-CSF barrier of the forebrain
consisted of a single claudin-11 positive cell layer (Figure 1C).
The Subarachnoid Space is Defined by Collagen
1 Immunoreactivity
The second trimester human fetal subarachnoid space between
the arachnoid blood-CSF barrier and the outer CSF-brain
barrier contained numerous bundles of collagen, many blood
vessels and a meshwork of leptomeningeal cells forming tra-
beculae. Immunostaining for collagen 1 clearly delineated the
subarachnoid space as shown in a section from a mid-gestational
human fetus in Figure 2A. The arachnoid barrier cell layer was
unstained in contrast to the strongly immunostained pial surface
layer which faced an unstained glial end feet layer. The base-
ment membranes of the pial blood vessels lost their collagen 1
immunoreactivity upon entering the end feet layer, revealed as a
continuous layer of glial end feet only interrupted by penetrat-
ing blood vessels after immunostaining for brain specific lipid-
binding protein (BLBP) (Figure 2B). The leptomeningeal cells in
the subarachnoid space including the arachnoid barrier cell layer
were positively stained for both YKL-40 and SSEA-4 (Figure 3)
but not for BLBP (Figure 2B). Where blood vessels penetrated
the end feet layer the subarachnoid space extended down into a
subpial compartment in the marginal zone. Double-labeling with
antibodies against BLBP and SSEA-4, showed SSEA-4 immunore-
activity of the pericytes and BLBP defined the outer invaginating
surface of the end feet layer, corresponding to the perivascular
Virchow-Robin space between vascular basement membrane and
surface of end feet (Figures 2B,C). The Virchow-Robin space is
obliterated when the glial and endothelial basement membranes
join (Brinker et al., 2014) consistent with depletion of BLBP and
SSEA-4 immunoreactivity.
From Radial Glial End Feet Layer, Characterized
by BLBP-, SSEA-4 and YKL-40 Immunoreactivity,
to Glia Limitans
Radial Glial End Feet Layer in Fetal Human Brain
In late embryos and early fetuses immunostained for BLBP,
SSEA-4, and YKL-40 the entire parenchymal lining of the
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FIGURE 1 | Distribution of claudin-11 immunoreactivity in sagittal
sections of E18 rat (A,B) and 21st wpc human (C) brain. (A)
Immunostaining for claudin-11 in a developing rat brain at E18 demonstrates
a strong reactivity of the entire arachnoid barrier cell layer (= arachnoid
blood-CSF barrier (aB-CSFB)) (arrowheads) in marked contrast to unstained
(Continued)
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FIGURE 1 | Continued
leptomeningeal cells in the subarachnoid space (SAS) and in the entire
brain. Cisterns at the base of the brain and cisterna magna (CM) are
well-developed. Note the very strongly stained arachnoid covering of the
tentorium cerebelli (TC) and the interrupted barrier cell layer where the
trigeminal nerve perforates the dura-arachnoid (arrow). The area outlined
with a rectangle is shown at higher magnification in (B) and demonstrates
that the barrier cell layer (aB-CSFB) covering the forebrain consists of a
strongly stained single cell layer. (C) At mid-gestation the human fetal
arachnoid barrier cell layer (aB-CSFB) is also formed by a single
claudin-11 positive cell layer. In (B,C) note that neither the E18 rat radial
glial end feet layer (EFL) and the pial surface layer forming the outer CSF
brain barrier (oCSF-BB) facing the subarachnoid space (SAS) nor the
human fetal radial glial end feet layer (EFL) and pial surface layer show
claudin-11 immunoreactivity. Scale bars: (A) 1000µm, (B) 50µm, (C)
100µm.
outer CSF-brain barrier, corresponding to radial glial end feet,
exhibited strong membranous immunoreactivity of the coni-
cally or deltoid shaped end feet with simple straight membranes.
The parenchymal lining in the second trimester showed mul-
tiple curly closely apposed delicate end feet membranes best
appreciated in a stacked series of confocal images of YKL-
40 stained marginal zone (Figure 3A). At mid-gestation the
individual end feet appeared as narrow densely packed paral-
lel tubules outlined by rather straight apical and apical-lateral
cell membranes (not shown). Double immunolabeling with anti-
bodies against BLBP and SSEA-4 (Figure 2C) and with anti-
bodies against YKL-40 and SSEA-4 (Figures 3A–C) demon-
strated that all end feet possessed a considerable overlapping
membrane-associated immunoreactivity for BLBP, SSEA-4 and
YKL-40.
Receptors and Transporters Associated with the End
Feet Layer
IL-13Rα2, which was recently shown to function as an YKL-
40/CHI3L1 receptor (He et al., 2013) and EAAT1/GLAST, a
well-known glutamate-aspartate influx transporter (also known
as Slc1a3), were used as representative examples to illustrate
dynamic functions of the end feet layer. Double-immunolabeling
of brains from human fetuses in the second trimester with
antibodies against IL-13Rα2 and YKL-40 (Figure 4A) showed
that the entire continuously YKL-40 immunoreactive end feet
layer contained evenly distributed IL-13Rα2 positive mem-
brane domains in infoldings of the end feet surface membrane.
Immunostaining with antibodies against the excitatory amino
acid influx transporter EAAT1 resulted in immunopositive punc-
tate or reticular structures along the membranes of the end feet
layer and surrounding blood vessels in the outer neocortex at
mid-gestation (Figure 4B). Double-immunolabeling with anti-
bodies against EAAT1 and YKL-40 (Figure 4C) showed a similar
distribution of influx transporter and YKL-40 within the end feet
layer and around blood vessels.
Glia Limitans in Adult Human Brain
Glia limitans, which forms the outermost part of the molecu-
lar layer in adult human cerebral cortex, consisted of a dense,
20–40µm thick network of intermingled GFAP-positive astro-
cytic processes and some small fibrous astrocytes, which were not
surface-associated (Figure 5A). These astrocytes and the outer
surface of the glia limitans were unstained following immuno-
histochemistry with an antibody against the neuronal marker
MAP2. The positive immunoreaction clearly defined the bor-
der zone toward the rest of the molecular layer (Figure 5B).
In some regions the outermost layer of the glia limitans con-
sisted of GFAP-negative empty-looking processes reminiscent
of second trimester end feet, referred to as remnants of end
feet (Figures 5A–C) that protruded into the subarachnoid space.
Many of these protrusions showed distinct apical membrane
reactivity for YKL-40 (Figure 5C). YKL-40 staining also revealed
many YKL-40 positive spheroid bodies corresponding to corpora
amylacea particularly within the glia limitans but also in the bor-
der zone toward the MAP2 positive part of the molecular layer
(Figure 5C) and in large perivascular spaces (not shown).
Discussion
The Arachnoid Barrier Cell Layer
Until recently the brain barriers in the developing brain were
considered absent or leaky by many investigators (see Discussion
in Saunders et al., 2014). Evidence is now emerging that these bar-
riers are functioning and adapted to fetal environment already in
the earliest stages of brain development (Saunders et al., 2012,
2013).
When the subarachnoid space is formed (see Table 2), the
arachnoid barrier cells facing the inner meningeal dural bor-
der cells have closely apposed cell membranes and are joined
to each other by numerous tight junctions. It has been shown
in many publications that this barrier cell layer is the structural
basis for the arachnoid blood-CSF barrier (see e.g., Nabeshima
et al., 1975). However, so far it is not known which tight junc-
tional proteins contribute to the paracellular diffusion restriction.
We tested the arachnoid blood-CSF barrier for the presence of a
number of different claudins using immunostaining and found
that claudin-11 may serve as a reliable marker for the arach-
noid barrier cells, as suggested from parallel finding in developing
mouse brain (Whish et al., 2015). Claudin-11, initially introduced
as oligodendrocyte-specific protein (OSP), is involved in forma-
tion of tight junctions and is best known for its implication in
interlamellar tight junction strands in oligodendrocytes (myelin
sheath tight junctions) as well as tight junction strands of the
Sertoli cells of the testes (the blood-testis barrier, Morita et al.,
1999; Morrow et al., 2010). Our results suggest that the arachnoid
blood-CSF barrier is present and characterized by claudin-11 in
early fetal life.
Since the arachnoid blood-CSF barrier is avascular and pro-
vides a relatively small surface area, it is believed that it does not
contribute significantly to blood-brain exchange (Abbott et al.,
2010). However, in light of recent findings of drug transporters
and drug-metabolizing enzymes in the arachnoid blood-CSF
barrier (Yasuda et al., 2013) and taken into account that the
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FIGURE 2 | Arachnoid blood-CSF barrier, subarachnoid space, pial
surface, and glial end feet layers immunostained for collagen 1 (A)
and double immunolabeled with antibodies against BLBP and
SSEA-4 (B,C) from occipital cortex of a 21st wpc human fetus. (A)
Immunostaining for collagen 1 depicts the limitation of the subarachnoid
space (SAS) of a 21st wpc human fetus. The arachnoid barrier cell layer
(aB-CSFB) is unstained (arrows) and the strongly immunostained pial surface
layer (PSL) faces an unstained glial end feet layer. The basement membranes
of the pial microvessels (BV) loose their stainability abruptly when the vessels
enter the end feet layer and fuse with the inner-most part of the PSL
(arrowheads). (B) In a section adjacent to that shown in (A), the entire end
(Continued)
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FIGURE 2 | Continued
feet layer is immunolabeled with anti-BLBP corresponding to the radial glial
end feet. Note the spaces in the end feet layer where blood vessels
penetrate into the parenchyma. (C) Double-labeling with antibodies against
BLBP and SSEA-4, nuclear stained with DAPI, reveals an evenly distributed
co-localization in the end feet layer. Where pial microvessels penetrate into
the marginal zone, the perivascular canals are lined with BLBP, revealing
Virchow-Robins space (illustrated with rectangles in B,C). The subarachnoid
space contains SSEA-4 positive leptomeningeal cells but shows no BLBP
reactivity. (B,C) same magnification. Scale bars: 100µm.
arachnoid barrier cell layer constitute a much larger fraction of
the brain surface area during early development, it is clear that
the arachnoid blood-CSF barrier is an important and changing
interface, that should not be ignored. It clearly warrants further
investigation in the developing and adult brain.
YKL-40/SSEA-4 in Outer CSF-Brain Barrier
After the penetration of the first vessels into the telencephalic
wall and the appearance of the choroid plexus the following mes-
enchymal/neuroectodermal interfaces comprise the initial brain
barrier system: (i) The blood-brain barrier proper across the
cerebral endothelial cells where YKL-40/SSEA-4 are present in
pericytes (Bjørnbak et al., 2014), (ii) the blood-CSF barrier at
the choroid plexus epithelium that is strongly YKL-40/SSEA-4
positive (Barraud et al., 2007; Bjørnbak et al., 2014), (iii) the
claudin-11 positive arachnoid blood-CSF barrier delineating the
subarachnoidal space which contains strongly YKL-40/SSEA-4
positive leptomeningeal cells and vessels, (iv) YKL-40/SSEA-4
positive pial microvessel blood-CSF barrier, and (v) an outer
CSF-brain barrier with a collagen 1 positive pial surface layer
covering a glial end feet layer comprising BLBP/SSEA-4/YKL-
40/IL-13Rα2 positive radial glial end feet. In addition, there is (vi)
an inner CSF-brain barrier interface between the ventricular CSF
and the brain interstitial fluid at the apical neuroepithelial cell
membranes linked by strap junctions (Møllgård et al., 1987) and
lined by dense YKL-40 immunoreactivity in the early developing
human.
In parallel to developmental processes at the inner CSF-brain
barrier, where strap junctions disappear when radial glial cells
differentiate to ependymal cells (see Whish et al., 2015), the
outer CSF-brain barrier seems to change character when themost
superficial subpial glial end feet layer transform into a subpial glia
limitans between 25 and 28 wpc in the human brain (Table 2).
An essential morphological feature of the blood-brain bar-
rier proper (BBB) lies in the presence of tight junctions between
the cerebral endothelial cells of the vasculature of the brain
parenchyma. Solute transport mechanisms and restrictions have
been studied thoroughly in developing and adult blood-brain
barrier and choroid plexuses blood-CSF barrier, discovering
distinct, comprehensive and changing transport systems, which
indicate that the choroid plexuses blood-CSF and blood-brain
barriers are functionally mature with respect to small molecules
in early development (Saunders et al., 2013). In contrast, lit-
tle is known about the developing outer CSF-brain barrier that
separates the outer CSF from the brain’s internal milieu. In the
rat brain Balslev et al. (1997) described an incomplete layer of
radial glial end feet as a part of the brain surface and large fen-
estrated sinusoid vessels in the subarachnoid space at E12, but
there was no albumin reactivity inside the marginal zone sug-
gesting that there must be some diffusional restriction to entry of
proteins even in early development. From E14 the pia-arachnoid
vessels became non-fenestrated and the developing end feet layer
was connected by junctional structures that changed over time
and offered restriction to protein penetration, most likely sup-
plemented by the basement membrane (Balslev et al., 1997). In
the present study we found immunostaining of the glial end
feet layer with both EAAT1 (glutamate transporter), IL-13Rα2
(YKL-40 receptor) and BLBP, which transports fatty acids (Kipp
et al., 2011) indicating that this outer CSF-brain barrier may
well be involved initially in controlling the transfer and diffu-
sion of solutes including morphogens into the brain and cellular
transmigration (see below).
Furthermore we observed that the closely packed layer of lep-
tomeningeal cells in the initial pial surface layer covering the
radial glial end feet became less coherent in parallel with the
formation of the glia limitans, indicating that the pial surface
layer contributes to diffusion restriction in early development, a
finding consistent with the results of Balslev et al. (1997).
YKL-40mRNA expression was strong in the pia-arachnoid tis-
sue and prominent YKL-40 staining was evident already from the
emergence of the meningeal tissues (Bjørnbak et al., 2014). Our
results suggest that YKL-40 is produced by the leptomeninges
and secreted into the subarachnoid space. Since the junctional
structures between glial end feet restrict diffusion and based on
the presence of the YKL-40 receptor IL-13Rα2, YKL-40 itself, as
shown by the pronounced immunoreactivity of the entire end
feet layer, is likely to be due to receptor-mediated uptake from
the subarachnoid space.
Involvement of Arachnoid Blood-CSF and Outer
CSF-Brain Barriers in Brain Inflammation
Until recently the central nervous system has been considered
an immune-privileged site, but it is now evident that monocyte-
derived macrophages also play an important role in its inflamma-
tion and maintenance of the functional plasticity of the healthy
brain (Schwartz et al., 2013). The brain is under constant immune
surveillance by both blood-born immune cells in leptomeningeal
and perivascular spaces and resident microglia (Engelhardt and
Coisne, 2011; Stolp et al., 2013). The brain barriers provide rel-
ative specialized immune privilege controlling leukocyte traf-
ficking, which is increased considerably during inflammation
and disease (Muldoon et al., 2013). Muldoon and colleagues
describe four routes for leukocyte CNS entry: (1) blood-to-
subarachnoid space via leptomeningeal vessels (pia microvessel
blood-CSF barrier); (2) blood-to-parenchymal perivascular space
through the BBB; (3) blood-to-cerebrospinal fluid via the choroid
plexus (choroid plexuses blood-CSF barrier); (4) blood-to-CSF
via meningeal spaces (arachnoid blood-CSF barrier) and through
the ependymal lining ventricles (inner CSF-brain barrier) (Ran-
sohoff et al., 2003; Engelhardt and Coisne, 2011; Muldoon et al.,
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FIGURE 3 | Arachnoid blood-CSF barrier, subarachnoid space, pial
surface, and glial end feet layers double immunolabeled with
antibodies against YKL-40 and SSEA-4 (A–C) in parietal cortex of a
15th wpc human fetus. Parietal cortex of a 15th wpc fetus, immunolabeled
with anti-YKL-40 (A) and anti-SSEA-4 (B), counterstained with DAPI and
(Continued)
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FIGURE 3 | Continued
merged (A1,B) in (C). The images are representations of a stacked
series of 10 steps, with 1µm intervals, processed as maximum
projection intensity. The staining of the end feet layer (EFL) shows
multiple delicate and curled end feet membranes. YKL-40
immunoreactivity is also present in the arachnoid blood-CSF barrier
(aB-CSFB in (A) and in leptomeningeal cells in the subarachnoid space
(arrows in A1). In (B) the pattern of SSEA-4 distribution is seemingly
equal to that of YKL-40, and the merged image of the stacked images
confirms the co-localization of YKL-40 and SSEA-4 in leptomeningeal
cells within the subarachnoid space (SAS) and in the end feet layer of
the radial glial cells (C). Scale bar: 10µm.
2013; Schwartz et al., 2013). In the subarachnoid space specific
antigen triggering enables the immune cell to penetrate the glia
limitans (outer CSF-brain barrier) (Bartholomaus et al., 2009;
Engelhardt and Coisne, 2011), which requires the activity of
matrix metalloproteinases MMP-2 and MMP-9 (Agrawal et al.,
2006). Thus, leucocyte trafficking involves all interfaces of the
brain barrier system.
It is generally believed that inflammation produces a break-
down of blood-brain barrier at some stages of brain development
(Stolp et al., 2005). Ichikawa and Itoh (2011) found that experi-
mental meningitis in rats at first caused increased permeability of
the arachnoid blood-CSF barrier rather than the BBB or choroid
plexuses blood-CSF barrier indicating, that breakdown of the
BBB and choroid plexuses blood-CSF barrier is secondary. How-
ever, further studies are necessary to clarify the role of arachnoid
blood-CSF and outer CSF-brain barriers in response to inflam-
mation in the developing brain. Nevertheless, the presence of an
early claudin-11 positive arachnoid blood-CSF barrier, diffusion
restraint through the outer CSF-brain barrier and distinct trans-
port systems and markers found in critical barrier sites in the
present study may be important for securing homeostasis and
normal immune function.
Brain Barriers, Inflammation and YKL-40
In a recent study of YKL-40 in the developing human fore-
brain, we showed a marked YKL-40 immunoreactivity in neu-
roepithelial cells, radial glial end feet, leptomeninges, and choroid
plexus epithelial cells in early stages. Later developmental fea-
tures included an increasing number of YKL-40 immunoposi-
tive pericytes particularly in the intermediate and subventricu-
lar zones and a population of small rounded YKL-40 positive
possible astroglial progenitors migrating along radial glial fibers
in the subventricular zone. The choroid plexus, glial end feet
and the astrocyte-resembling cells observed in the developing
hippocampus were strongly YKL-40 immunopositive (Bjørnbak
et al., 2014). In the present study we confirmed the YKL-40 reac-
tivity and found overlapping immunostaining of SSEA-4 and
YKL-40 in leptomeningeal cells and the end feet layer.
Current knowledge suggests that neuroinflammation is of
great importance in almost all neurological disorders, and that
interaction between the brain barriers and the immune system
contribute to this process (Stolp et al., 2013). YKL-40 immunore-
activity is specifically detected at sites of brain barriers and
entry points for microglia in the developing human brain and
is known to be involved in angiogenesis, inflammation and is
overexpressed in glioblastoma (brain cancer, GBM) (Lal et al.,
1999; Nigro et al., 2005; Colin et al., 2006) and brain tissue
and/or CSF in several neurological disorders that commence in
the developing brain or/and involve dysfunction of brain barriers
(Chung et al., 2003; Colton et al., 2006; Arion et al., 2007; Gar-
bett et al., 2008; Bonneh-Barkay et al., 2010). YKL-40 has also
been found to regulate MMP-2 (Ku et al., 2011) and MMP-9 in
some cases (Michelsen et al., 2010). The general spatio-temporal
distribution of YKL-40 immunoreactivity suggests that YKL-40
secretion from choroid plexus epithelium, leptomeningeal cells
and pericytes is involved in controlling local angiogenesis, access
of peripheral cells (microglia and perhaps macrophages) to the
developing brain and its specialized immunity. The correlation
between YKL-40 and MMPs, presence of YKL-40 in brain barri-
ers and necessity of MMP-2 and MMP-9 in immune cell trans-
migration through the glia limitans further support the hypothe-
sis, that YKL-40 has a role in immune cell transmigration across
brain barriers. Whether YKL-40 expression in the brain barriers
is increased in response to neuroinflammation warrants further
investigation.
Stem Cells, Brain Barriers and SSEA-4
In a previous study of human embryonic central nervous sys-
tem, the stage-specific embryonic antigen-4 (SSEA-4) was found
in neural progenitor cells in forebrains of human embryos and
early fetuses (Barraud et al., 2007), and was shown in a population
of differentiating cells in an intermediate stage between pluripo-
tent human embryonic stem cells (hESCs) and neural progenitor
cells (Noisa et al., 2012). SSEA-4 belongs to the group of globo-
series glycosphingolipids, and is widely used in characterization
of hESC lines (Adewumi et al., 2007). Furthermore, it is highly
expressed in GBM compared to normal tissue and an SSEA-4 spe-
cific antibody suppresses GBM tumor growth in mice (Lou et al.,
2014). In other cancers SSEA-4 has been established as a cancer
stem cell marker (Malecki et al., 2012; Noto et al., 2013). The
glycoprotein YKL-40 has been associated with hESC and neu-
ral stem cell differentiation (Brøchner et al., 2012), and a marked
similarity of the distribution patterns in developing human fore-
brain was noted (Barraud et al., 2007; Bjørnbak et al., 2014). In
this study the localization of YKL-40 and SSEA-4 was almost
identical corresponding to earlier findings. The role of SSEA-4 in
brain barriers remains to be elucidated but its known presence
in hESC, GBM and cancer stem cells and co-localization with
YKL-40 in the brain barriers suggest that the outer brain barriers
participate in organization and development of the brain through
several different mediators including SSEA-4.
BLBP and the Morphogenetic Role of Meninges
Brain specific lipid-binding protein (BLBP) is a member of
the lipid-binding protein family that carries small hydrophobic
signaling molecules between cellular compartments but also a
marker of radial glial cells (Feng et al., 1994; Howard et al., 2006),
astrocytes (Kipp et al., 2011) and adult neural stem cells (mice)
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FIGURE 4 | Marginal zone in parietal cortex of a 15th wpc human
fetus double immunolabeled with antibodies against YKL-40 and
IL-13Rα2 (A) and in occipital cortex of a 21st wpc human fetus (B,C)
labeled with antibodies against EAAT1 (B) and against EAAT1 and
YKL-40 (C). Parietal cortex of a 15th wpc fetus, immunolabeled with
antibodies against IL-13Rα2 and YKL-40, merged and nuclear
counterstained with DAPI (A). The YKL-40 immunoreactive end feet layer
contains evenly distributed interleukin-13Rα2 receptors (white arrowheads).
(B) The excitatory amino acid transporter (EAAT1) is visualized in occipital
cortex of a 21st wpc fetus, below the subarachnoid space (SAS) within the
end feet layer (EFL) and in surrounding parenchymal blood vessels (BV). The
merged image with YKL-40 (C) shows a similar distribution within the end
feet layer and around the blood vessels. (A) Scale bar: 20µm. (B,C) same
magnification. Scale bar: 50µm.
(Giachino et al., 2014). BLBP expression is increased in brain
tumor tissue and associated with progression and/or decreased
survival in glioblastoma (GBM). Depending on the ratio of fatty
acid ligands BLBP can increase or decrease migration in GBM
(Kipp et al., 2011). A variety of secreted diffusible factors from
fetal meninges regulate neural migration and positioning and
organize the pial basement membrane, which is a critical anchor
point for the radially oriented fibers of neuroepithelial stem cells
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FIGURE 5 | Glia limitans in adult human brain stained for GFAP,
MAP2, and YKL-40 (A–C). Adult human cerebral cortex immunostained for
GFAP in (A) depicts the glia limitans (GL) as a dense multilayered network of
GFAP positive astrocytic processes and few small fibrous astrocytes
(arrowheads). Note the larger protoplasmic astrocytes (arrows) deeper in the
molecular layer. Protrusions of astrocytic processes, which look like remnants
of end feet (RE) are seen as patches facing the subarachnoid space (SAS).
Immunostaining for MAP2 (B) defines the inner border of glia limitans (GL)
toward the rest of the molecular layer and the unstained outer border with
the empty-looking protrusions/remnants of end feet (RE) toward the
subarachnoid space (SAS) is clearly depicted. Immunoreactivity for YKL-40
of glia limitans (GL) is seen in (C). Many protrusions exhibit distinct apical
membrane reactivity for YKL-40, and YKL-40 positive spheroid bodies
corresponding to corpora amylacea are seen within the glia limitans but also
in the border zone toward the MAP2 positive part of the molecular layer
(arrowheads). (A–C) same magnification. (A) Scale bar: (A) 20µm.
(Siegenthaler and Pleasure, 2011). Signaling molecules identi-
fied so far include the chemokine SDF-1, BMP7, and the mor-
phogen all-trans retinoic acid (atRA) which seems to be involved
in the decision of neuroepithelial cells to generate neurons and
intermediate progenitor cells (IPCs) destined for the subventric-
ular zone via communications with adjacent radial glial end feet
(Siegenthaler et al., 2009). Feng et al. (1994) suggested that BLBP
mediates aspects of neuron-glia interaction and is involved in
neural differentiation and maintenance of the glial fiber scaffold.
We found BLBP in the end feet layer in the developing outer
CSF-brain barrier, establishing BLBP as a reliable marker for the
radial glial end feet layer and thereby the outer CSF-brain bar-
rier. Furthermore, BLBP has a preference for binding long chain
polyunsaturated fatty acids with a possible ligand (Xu et al., 1996)
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being docosahexaenoic acid, also involved in CNS development
(Xu et al., 1996), which in light of our findings support that BLBP
in the outer CSF-brain barrier participate in neural development
and positioning possibly also orchestrated from the meninges.
Concluding Remarks
Research regarding the brain barrier system has evolved consid-
erably over the last decades and now the focus is on both phys-
ical, transport, and metabolic barrier properties. In this study
we described the changing barriers at the surface of the devel-
oping brain, but to characterize and understand these com-
plex structures and their interaction, we found it necessary to
revise the barrier concept based merely on anatomical features.
Furthermore, the terminology in this area is at best confus-
ing and inconsistent. Based on these considerations we argued
that the outer brain barriers consist of (i) an arachnoid blood-
CSF barrier across the arachnoid barrier cell layer, (ii) a pial
microvessel blood-CSF barrier across the pial microvessels and
(iii) an outer CSF-brain barrier across the radial glial end feet
layer covered by a pial surface layer and later in development
glia limitans with accompanying pial basement membrane. Our
findings of claudin-11 in the arachnoid blood-CSF barrier and
EAAT1 and IL-13Rα2 in the outer CSF-brain barrier confirm
their barrier properties and the spatiotemporal distribution of
YKL-40/BLBP/SSEA-4 further establish the necessity of regard-
ing these interfaces as separate entities, since they may play
different roles in normal brain development and possibly in
several neurological disorders. We therefore propose an elab-
oration of the model for developing brain barriers as defined
by Saunders et al. (2008) and divide the brain interfaces into
six barriers at three different sites: (1) The blood-brain bar-
rier proper (i), (2) the blood-CSF barrier constituting (ii) the
choroid plexuses blood-CSF barrier across the choroid plexus,
(iii) the arachnoid blood-CSF barrier across the arachnoid barrier
cell layer and (iv) the pial microvessel blood-CSF barrier across
the pial microvessels; (3) The CSF-brain barrier comprising (v)
the outer CSF-brain barrier (described earlier in this paragraph)
and (vi) inner CSF-brain barrier across the ventricular zone
cell layer.
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